

07 Jul 2022 | News

## New Chinese-Language Podcast: 中国生物医药行业热点话题讨论

*Hot Topic Chat*

by Brian Yang

Join our China-based content team for this inaugural Chinese-language podcast discussing selected recent hot topics impacting the biopharma industry in China, including bispecific antibodies, antibody-drug conjugates and new regulatory policies designed to speed product approvals.

Brian Yang and Dexter Yan discuss recent hot topics in China's biopharma industry in this new podcast chat series (Chinese-language description below).

On 29 June, China officially approved its first bispecific anti-PD-1/CTLA4 antibody for cervical cancer. The move also marked the new addition of another immuno-oncology contender to an already highly competitive market.

Also in June, the National Medical Products Administration issued a policy to accelerate the approval of new drugs from overseas and with large clinical need, drugs to treat orphan and pediatric conditions, and products for major infectious diseases. Related measures included improving communications with foreign pharma firms, in China's latest bid to attract and retain foreign investment in the country, amid Beijing's draconian "COVID Zero" policy and months-long lockdowns in Shanghai and other parts of the country.

The latest developments in antibody-drug conjugates are also discussed in this episode, designed to help you understand what's hot in China's biopharma development sphere.

If you have any suggestions, ideas or comments, please contact the authors via the addresses in the byline box above.

XXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXXBrianXXXXXXXXXXXXDexterXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXPD-1/CTLA-4XXXXXXXXXXXXXXXXXXXXCadonilimabXXXXXXXXXXXX (Also see "[China Approves World's First Bispecific IO Drug Amid PD-1/L1 Glut](#)" - Scrip, 1 Jul, 2022.)

XXPD-1XXXXXXXXXXXXXXXXXXXX

XX  
XXXXXXXXXXXXXXXXXXXX (Also see "[Invitation Extended: New Chinese Policies Aim To Lure Foreign Pharma Firms](#)" - Pink Sheet, 1 Jul, 2022.)

XX“XXXXXX”XXXXXXXXXXXX  
XXXXXXXXXXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXXADCXXXXXXXXXXXXXXXXXXXXSino BiopharmaceuticalXXXXXXXXXXXXInvoX  
1.61XXXXXXXXXXXXXXXXXXXXF-star Therapeutics (Also see "[Asia Deal Watch: invoX Builds Novel Pipeline Through \\$161m F-star Acquisition](#)" - Scrip, 24 Jun, 2022.)

2022XX

XX“XX  
”XXXXXXXXXXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXX

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

[Click here to explore this interactive content online](#) ✨